

# Vincenzo Cuccurullo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7407902/publications.pdf>

Version: 2024-02-01

46  
papers

782  
citations

430874

18  
h-index

552781

26  
g-index

54  
all docs

54  
docs citations

54  
times ranked

989  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone Metastases Radiopharmaceuticals: An Overview. <i>Current Radiopharmaceuticals</i> , 2013, 6, 41-47.	0.8	54
2	A Preservation Method That Allows Recovery of Intact RNA from Tissues Dissected by Laser Capture Microdissection. <i>Analytical Biochemistry</i> , 2002, 300, 139-145.	2.4	38
3	Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology. <i>Current Radiopharmaceuticals</i> , 2009, 2, 224-253.	0.8	37
4	Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer. <i>Current Radiopharmaceuticals</i> , 2013, 6, 57-71.	0.8	36
5	PET/MRI and the revolution of the third eye. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1519-1524.	6.4	35
6	Peptide Imaging with Somatostatin Analogues: More than Cancer Probes. <i>Current Radiopharmaceuticals</i> , 2013, 6, 36-40.	0.8	35
7	Microvascular Invasion in HCC: The Molecular Imaging Perspective. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-10.	0.8	30
8	Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers. <i>Journal of Cellular Physiology</i> , 2017, 232, 270-275.	4.1	28
9	MRI in Pregnancy and Precision Medicine: A Review from Literature. <i>Journal of Personalized Medicine</i> , 2022, 12, 9.	2.5	28
10	Nuclear medicine in prostate cancer: A new era for radiotracers. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 70.	0.5	26
11	<sup>18</sup> F-fluoromethylcholine or <sup>18</sup> F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. <i>Nuclear Medicine and Biology</i> , 2015, 42, 340-348.	0.6	25
12	Role of PET and SPECT in the Study of Amyotrophic Lateral Sclerosis. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	24
13	Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. <i>Nuclear Medicine Review</i> , 2017, 20, 49-56.	0.5	24
14	Neurological applications for myocardial MIBG scintigraphy. <i>Nuclear Medicine Review</i> , 2013, 16, 35-41.	0.5	22
15	Inflammatory bowel disease: value in diagnosis and management of MDCT-enteroclysis and <sup>99m</sup> Tc-HMPAO labeled leukocyte scintigraphy. <i>Abdominal Imaging</i> , 2011, 36, 372-381.	2.0	20
16	Toward tailored medicine (and beyond): the pheochromocytoma and paraganglioma model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1262-1265.	6.4	20
17	The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence. <i>Diagnostics</i> , 2019, 9, 127.	2.6	19
18	Parotid function after selective deep lobe parotidectomy. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2007, 45, 108-111.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Current Radiopharmaceuticals, 2017, 10, 74-84.	0.8	17
20	Diagnostic Imaging in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2014, 55, 1576-1577.	5.0	16
21	99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other) Tj ETQq1 1 0.784314 rgBT /Over	0.8	16
22	Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?. Current Radiopharmaceuticals, 2019, 12, 156-170.	0.8	16
23	Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?. Journal of Nuclear Medicine, 2014, 55, 1401-1403.	5.0	15
24	Targeted Therapy Towards Cancer-A Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 311-317.	1.7	13
25	Small-Animal Molecular Imaging for Preclinical Cancer Research: <sup>18</sup> F PET and <sup>111</sup> In SPECT. Current Radiopharmaceuticals, 2016, 9, 103-113.	0.8	13
26	Hybrid SPECT/CT Imaging in Neurology. Current Radiopharmaceuticals, 2014, 7, 5-11.	0.8	12
27	Second-Generation 3D Automated Breast Ultrasonography (Prone ABUS) for Dense Breast Cancer Screening Integrated to Mammography: Effectiveness, Performance and Detection Rates. Journal of Personalized Medicine, 2021, 11, 875.	2.5	11
28	Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours. Current Radiopharmaceuticals, 2019, 12, 98-106.	0.8	10
29	Scintigraphic evaluation of oesophageal transit during radiotherapy to the mediastinum. BMC Gastroenterology, 2008, 8, 51.	2.0	8
30	<sup>18</sup> F FDG-PET/CT in Traumatic Brain Injury Patients: The Relative Hypermetabolism of Vermis Cerebelli as a Medium and Long Term Predictor of Outcome. Current Radiopharmaceuticals, 2014, 7, 57-62.	0.8	8
31	Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?. Indian Journal of Radiology and Imaging, 2017, 27, 509-516.	0.8	8
32	PET/CT in thyroid cancer – the importance of BRAF mutations. Nuclear Medicine Review, 2020, 23, 97-102.	0.5	7
33	Nuclear medicine in multiple myeloma – more than diagnosis. Nuclear Medicine Review, 2010, 13, 32-8.	0.5	7
34	From Homo sapiens to Homo in nexu (connected man): could functional imaging redefine the brain of a “new human species”? European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1385-1387.	6.4	6
35	Whole stomach transposition without gastric drainage procedure: a good surgical option to restore digestive continuity after esophagectomy. International Surgery, 2007, 92, 73-7.	0.1	5
36	The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment. Diagnostics, 2021, 11, 863.	2.6	4

#	ARTICLE	IF	CITATIONS
37	Tailored Molecular Imaging of Pheochromocytoma and Paraganglioma: Which Tracer and When. <i>Neuroendocrinology</i> , 2022, 112, 927-940.	2.5	4
38	Our experience in thymic hyperplasia using <sup>67</sup> Ga-citrate, <sup>111</sup> In-pentetreotide and <sup>201</sup> Tl-chloride. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1616-1616.	6.4	3
39	A SIMPLE SIGN FOR THE DIFFERENTIAL DIAGNOSIS OF THE CONGENITAL TRIGGER THUMB. <i>Plastic and Reconstructive Surgery</i> , 1999, 103, 748-749.	1.4	2
40	FDG-CT/PET false positive case in hip prosthesis: a clue to avoid error. <i>Radiology Case Reports</i> , 2021, 16, 2601-2604.	0.6	2
41	Continuous Monitoring of Left Ventricle Function by VEST in Hemodialyzed Patients. <i>Seminars in Nephrology</i> , 2006, 26, 80-84.	1.6	1
42	Diagnostic Imaging and Pathology. <i>Current Clinical Pathology</i> , 2016, , 107-111.	0.0	1
43	Surgical treatment of differentiated thyroid carcinoma: a retrospective study. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2206.	3.0	1
44	Meet Our Associate Editor. <i>Current Radiopharmaceuticals</i> , 2016, 9, 3-3.	0.8	0
45	Will <sup>68</sup> Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 103-109.	0.2	0
46	Peculiar Aspects and Problems of Diagnostic Nuclear Medicine in Paediatrics. , 2016, , 1-18.		0